[Pathology and pathogenesis of pituitary corticotroph adenoma].
Corticotroph adenoma is a benign tumor composed of adenohypophyseal cells; carcinoma with metastasis and ectopic adenoma have also been reported. In our pathological series, the frequency of this type of adenoma is 13% (250/1863 tumors removed between 1970 and 2001). Usually, corticotroph adenomas synthesize peptides derived from POMC maturation: ACTH, ss-endorphine, and ssLPH. In the great majority of cases, ACTH induces hypercorticism with clinical and biological signs of Cushing's disease. However, some tumors the pathologist identifies as corticotroph adenomas are not associated with clinical signs of hypercorticism (20% of the corticotroph adenomas in our series). Corticotroph adenoma is a basophilic or chromophobe tumor composed of cells which remain regulated by cortisol. This may explain the small size of this type of adenoma in 80% of the cases. In contrast, "silent" adenomas or macroadenonas which synthesize high-weight POMC are aggressive invasive tumors. Neurosurgery is indicated for the treatment of corticotroph adenoma. Recurrence is explained by incomplete removeal of the tumor. Peroperative studies may be necessary to find microadenomas. In some cases, the whole pituitary must be removed and cut in serial sections to find a tumor measuring<2 mm. In our opinion, the existence of corticotroph hyperplasia inducing Cushing's disease remains to be proven (we have never observed one). The pituitary origin of the tumor is based on its monoclonality. The general mechanism of tumorigenesis is known, but the specific factors involved and markers of aggressiveness remain to be discovered.
Trouillas
J
J
Laboratoire d'Histologie et d'Embryologie Moléculaires, Unité INSERM U433, Faculté de Médecine Lyon-RTH Laennec, rue G.-Paradin, 69372 Lyon Cedex 08, France. lhem@laennec.univ-lyon1.fr
D000236:Adenoma / Q000150:complications / Q000235:genetics / Q000378:metabolism / Q000473:pathology*; D000324:Adrenocorticotropic Hormone / Q000378:metabolism; D000818:Animals; D014408:Biomarkers, Tumor / Q000032:analysis; D018797:Cell Cycle Proteins / Q000235:genetics / Q000502:physiology; D003346:Corticotropin-Releasing Hormone / Q000378:metabolism; D003480:Cushing Syndrome / Q000209:etiology; D016207:Cytokines / Q000502:physiology; D006133:Growth Substances / Q000502:physiology; D006801:Humans; D006965:Hyperplasia; D007030:Hypothalamo-Hypophyseal System / Q000503:physiopathology; D051379:Mice; D018345:Mice, Knockout; D008822:Mice, Transgenic; D009363:Neoplasm Proteins / Q000032:analysis; D010903:Pituitary Gland, Anterior / Q000473:pathology*; D010911:Pituitary Neoplasms / Q000150:complications / Q000235:genetics / Q000378:metabolism / Q000473:pathology*; D010913:Pituitary-Adrenal System / Q000503:physiopathology; D011333:Pro-Opiomelanocortin / Q000378:metabolism; D011965:Receptors, Glucocorticoid / Q000235:genetics / Q000502:physiology; D012189:Retrospective Studies; D001615:beta-Endorphin / Q000378:metabolism; D008083:beta-Lipotropin / Q000378:metabolism
D014408:Biomarkers, Tumor; D018797:Cell Cycle Proteins; D016207:Cytokines; D006133:Growth Substances; D009363:Neoplasm Proteins; D011965:Receptors, Glucocorticoid; D001615:beta-Endorphin; D011333:Pro-Opiomelanocortin; D000324:Adrenocorticotropic Hormone; D003346:Corticotropin-Releasing Hormone; D008083:beta-Lipotropin
Histopathologie et tumorigenèse de l'adénome hypophysaire corticotrope.